https://vist.ly/4arwp | Pharma is changing fast. Biotech’s lean models and direct-to-consumer moves are shaking up the old rules. Patients have more power, and delivery innovations are driving billion-dollar deals. Want to know what’s next? Dive into our latest insights on modular biopharma, royalty financing, and consumer-led innovation.
Evaluate Ltd
Information Services
Evaluate provides trusted commercial intelligence and predictive analytics to the pharmaceutical industry
About us
Evaluate provides trusted commercial intelligence and forecasting models for the pharmaceutical industry. We help our clients to refine and transform their understanding of the past, present and future of the global biopharma market to drive better decisions. Evaluate solutions give you the time and confidence to turn understanding into insight, and insight into action. Evaluate Pharma - the trusted global view of the pharmaceutical market’s past, present and future performance with consensus forecasts to 2030, company financials, pipelines, deals and more. Evaluate Omnium - provides a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, delivering game-changing insight into pharma asset potential. Forecasting Solutions - Ensure precise and efficient forecasting at every stage of your product lifecycle. Our comprehensive suite of forecasting solutions tailored to the pharmaceutical industry, including software, cloud-based platforms, custom-built models, advanced analytics and data. Our forecasting solutions support forecasters through new product planning, launch, and commercialisation. CDMO Intelligence - Access CDMO screening, molecular landscape insights, detailed manufacturing capabilities, and accurate volume forecasts. You’ll have a wealth of data and industry insights at your fingertips, backed by gold standard financial forecast methodologies. Consulting and Analytics - Evaluate’s consulting and analytics team is here to help clients address unique scientific, clinical and commercial challenges. We answer key asset, portfolio strategy, and corporate strategy-related business questions, powered by the combined resources of Norstella, one of the world’s largest pharma intelligence solutions providers. Evaluate’s combination of leading data sources, deep pharma expertise, robust methodologies, data science and real-world data will ensure your teams make the right decisions to drive your growth.
- Website
-
http://www.evaluate.com
External link for Evaluate Ltd
- Industry
- Information Services
- Company size
- 51-200 employees
- Headquarters
- London
- Type
- Privately Held
- Founded
- 1996
- Specialties
- pharma business analysis, pharma licensing deals, pharma consensus forecasts, biotech business analysis, pharma competitive intelligence, medtech consensus forecasts, pharma business developement, pharma R&D analysis, pharma data, pharma forecasting models, Real World Data, Pharma portfolio strategy, Pharma Consulting, and BD&L consulting
Locations
-
Primary
Get directions
3 More London Riverside
London, SE1 2RE, GB
-
Get directions
60 State St
Boston, Massachusetts 02109, US
-
Get directions
Akasaka Garden City 4F, 4-15-1 Akasaka,
Tokyo, Tokyo 107-0052, JP
Employees at Evaluate Ltd
Updates
-
A sizeable portion of biopharma’s revenues are at risk. But not all loss-of-exclusivities are created equal, so who is really under pressure? In our latest report, we dig into the data to understand the portfolio strategies that can help bridge the growth gap. Download the report ahead of our webinar on 29th October: https://vist.ly/4akwu
-
-
Evaluate Ltd reposted this
🔥 Hot Job Alert! Evaluate Ltd is hiring for a Senior Solution Consultant, Life Sciences Forecasting in the United States (Remote). Apply here: https://vist.ly/4aij5 In this role, we are seeking someone with an entrepreneurial mindset who can drive pre-sales efforts for life sciences forecasting solutions’ subscriptions and consulting/services opportunities. If this sounds like the perfect role for you, apply now—or share this opportunity with someone who might be a great fit.
-
-
Explore the forces reshaping the global pharma market. https://vist.ly/4ahad Step into the 2025 World Preview content hub, your gateway to insights and strategic analysis looking ahead to 2030. By exploring the hub, you'll gain the tools to: • 🔍 Forecast Future Market Trends • 🌍 Track Global Competitive Shifts • 💊 Benchmark Products & Pipelines • ⚖️ Evaluate Patent Exposure • 🤝 Monitor M&A Activity Click the link above to visit the hub and gain access to the insight.
-
Get early access to insights from our upcoming report: “Pharma v Biotech: New Rules?” https://vist.ly/4agpx The boundaries between pharma and biotech are shifting. Funding pressures, policy changes, and new business models are redefining how innovation reaches patients. This preview article reveals: • Why biotechs are becoming leaner and more independent • How pharma is moving towards direct-to-patient channels • Why convenience, affordability and access now matter as much as innovation Stay ahead with this guide to the new rules of pharma and biotech.
-
-
Looking to strengthen your drug pipeline with some in-licensed assets? Our expert consultants have some guidance to ensure that you identify the assets that align with your strategy. Check out our best practices webinar now 👉 https://vist.ly/4adgy
-
【1週間前・ご登録はお早めに】 Healthcare Intelligence Day2025✨ ― 業界最高水準のデータとコンサルティングを通じて医薬品業界の未来を変える https://vist.ly/4absy 日時：10月21日（火）13時より 開催方式：オンライン 本イベントでは、私たちが提供する「インテリジェンス」が、未来の医薬品開発と商業化をどう変革しうるのか、その可能性を探ります。 有識者による講演を通じて、業界の最新動向や未来の展望を共有するだけでなく、製薬企業が直面する複雑な課題に対し、データとインサイトがどのように意思決定を支え、成功へ導くのかを、具体的な事例とともにご紹介します。 医薬品開発の未来を、共に描く一日。 ぜひご参加ください。 #医薬品開発 #医薬品 #製薬 #HealthcareIntelligenceDay2025
-
-
What’s the secret formula for creating the next pharmaceutical behemoth? https://vist.ly/4a8y9 This eBook features analyses using Evaluate Pharma data. Discover whether indication expansion drives revenue growth, the pros and cons of in-house vs. outsourced development, and more.
-
-
Are you attending Bio-Europe Fall? We are, too! Join us for a discussion that could redefine your strategy. Book a meeting with us to access our partnering system: https://vist.ly/4a8fu More info about Bio-Europe: https://vist.ly/4a8f2
-
-
DOWNLOAD: The lines between pharma and biotech are blurring. https://vist.ly/49yu6 As funding tightens and policy shifts, both sectors are adapting, with biotechs becoming leaner and more independent, and pharma exploring new business models and direct-to-patient channels. Convenience, affordability, and access are now as important as innovation. Our deep dive into this topic is still taking shape, but you can get a preview in this summary article.
-